Skip to content

Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Patients With Recurrent Respiratory Papillomatosis

Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Patients With Recurrent Respiratory Papillomatosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052148
Enrollment
Unknown
Registered
2021-10-20
Start date
2021-11-01
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile onset recurrent respiratory papillomatosis (JORRP)

Interventions

Experimental group:THRIVE
Control group:apnea

Sponsors

Beijing Tongren Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 12 Years

Inclusion criteria

Inclusion criteria: Pediatric patients aged 1 to 12 years with symptomatic JORRP requiring operative intervention under general anesthesia at the Beijing Tongren Hospital.

Exclusion criteria

Exclusion criteria: 1. The guardian refuses to sign the informed consent; 2. There is at least one high-flow contraindication (epistomiasis, known or suspected skull base fracture or abnormality, nasal blockage, nasal bone fracture, abnormal nasal blood vessels, cerebrospinal fluid leakage, pulmonary tuberculosis,); 3. Tracheostomy patients; 4. Congenital heart disease or lung disease.

Design outcomes

Primary

MeasureTime frame
apnoea time until one of the termination criteria was reached;Transcutaneous CO2;arterial blood gases;

Secondary

MeasureTime frame
minimum oxygen saturation;perioperative vital indexes;satisfaction of surgeon;

Countries

China

Contacts

Public ContactWang Guyan

Beijing Tongren Hospital Affiliated to Capital Medical University

guyanwang2006@163.com+86 13910985139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026